Astellas Pharma (4503) AI Stock Analysis

• Market Cap: $2.91T
• Dividend Yield: 4.58%
• Average Volume (3M): 7.40M
• Price to Earnings (P/E): 35.5
• Beta (1Y): 0.49
• Revenue Growth: 14.29%
• EPS Growth: 368.64%
• Country: JP
• Employees: 14,754
• Sector: Healthcare
• Sector Strength: 38
• Industry: Drug Manufacturers - General
• EPS (TTM): 38.22
• Shares Outstanding: 1,809,663,100
• 10 Day Avg. Volume: 8,426,540
• 30 Day Avg. Volume: 7,402,606
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 1.11
• Enterprise Value/Revenue: 1.68
• Enterprise Value/Gross Profit: 2.15
• Enterprise Value/Ebitda: 7.39
• 1Y Price Target: $1,630.34
• Price Target Upside: 0.92% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 74 Outperform
• Price Target: ¥1,768.00 ▲(9.44% Upside)

Astellas Pharma's overall score is driven by strong financial performance and a positive outlook from the recent earnings call. The primary strength lies in robust revenue growth and strategic brand success. However, high valuation metrics and overbought technical indicators present potential risks.

Positive Factors

Earnings Projections

Future earnings will be the catalysts with projected EPS growth of 37% CAGR 2024-2027.

Growth Trajectory

Padcev's growth acceleration is redefining Astellas's growth trajectory.

Negative Factors

Loss of Exclusivity Impact

Astellas's bottomline should weather Xtandi LOE better than the topline.

Astellas Pharma Business Overview & Revenue Model

Company Description

Astellas Pharma Inc. is a Japanese multinational pharmaceutical company headquartered in Tokyo, Japan. The company focuses on innovative drug development, primarily targeting therapeutic areas such as oncology, urology, immunology, nephrology, and neuroscience. Astellas is committed to improving the health and well-being of people around the world by providing cutting-edge pharmaceutical solutions.

How the Company Makes Money

Astellas Pharma makes money primarily through the research, development, manufacturing, and sale of pharmaceutical products. Its revenue is generated from the sales of prescription drugs and other healthcare products within its core therapeutic areas. The company invests significantly in research and development to discover new drugs and bring them to market, thus driving future revenue growth. Additionally, Astellas may engage in strategic partnerships and collaborations with other pharmaceutical companies, research institutions, and biotechnology firms to enhance its product offerings and expand its market reach. These collaborations can include co-development agreements, licensing deals, and joint ventures that contribute to its earnings. The company's global presence and diverse product portfolio allow it to capture revenue from various markets worldwide.

Astellas Pharma Financial Statement Overview

Summary

Astellas Pharma shows strong financial performance with robust revenue growth, high gross profit margins, and improved net profit margins. The balance sheet indicates a reduction in leverage and solid cash flow generation, reflecting strong liquidity and financial flexibility. Despite these strengths, there is room for improving operational efficiency and shareholder value.

Income Statement

Astellas Pharma demonstrates strong revenue growth with a 19.22% increase from 2024 to 2025. The gross profit margin remains high at 74.57% for 2025, indicating effective cost management. The net profit margin improved significantly from 1.06% in 2024 to 2.65% in 2025. However, the EBIT margin slightly decreased to 13.37% in 2025, suggesting potential challenges in operational efficiency. Overall, the company shows strong growth and profitability trends.

Balance Sheet

Astellas Pharma maintains a solid equity base with an equity ratio of 45.32% in 2025. The debt-to-equity ratio improved to 0.55, reflecting a decrease in leverage and financial risk. Return on Equity (ROE) increased to 3.35% in 2025, indicating better utilization of shareholders' equity. Despite the improvements, the relatively low ROE suggests there is room for enhancing shareholder value.

Cash Flow

The company exhibits robust cash flow generation, with a free cash flow growth rate of 82.95% from 2024 to 2025. The operating cash flow to net income ratio is 3.97, reflecting strong cash flow relative to net income. The free cash flow to net income ratio is 3.24, indicating effective conversion of profits into cash. These metrics highlight Astellas Pharma's strong liquidity and financial flexibility.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.91T	1.60T	1.52T	1.30T	1.25T
Gross Profit	1.43T	1.31T	1.23T	1.04T	1.00T
EBITDA	248.30B	195.34B	240.46B	241.03B	219.83B
Net Income	50.75B	17.05B	98.71B	124.09B	120.59B
Balance Sheet
Total Assets	3.34T	3.57T	2.46T	2.33T	2.27T
Cash, Cash Equivalents and Short-Term Investments	188.37B	335.69B	396.62B	337.28B	331.69B
Total Debt	831.43B	1.01T	200.01B	212.74B	278.26B
Total Liabilities	1.83T	1.97T	948.56B	872.09B	887.51B
Stockholders Equity	1.51T	1.60T	1.51T	1.46T	1.39T
Cash Flow
Free Cash Flow	164.61B	89.98B	239.23B	181.00B	229.40B
Operating Cash Flow	201.61B	172.47B	327.77B	257.44B	306.84B
Investing Cash Flow	-96.52B	-845.80B	-84.50B	-62.41B	-81.89B
Financing Cash Flow	-261.37B	614.06B	-195.62B	-216.30B	-229.48B

Astellas Pharma Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1615.50
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4503, the sentiment is Positive. The current price of 1615.5 is above the 20-day moving average (MA) of 1504.33, above the 50-day MA of 1437.92, and above the 200-day MA of 1469.51, indicating a bullish trend. The MACD of 51.20 indicates Negative momentum. The RSI at 75.30 is Negative, neither overbought nor oversold. The STOCH value of 94.01 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4503.

Astellas Pharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4507	83 Outperform	$2.32T	12.53	13.71%	2.17%	4.04%	21.20%
4528	74 Outperform	$801.92B	18.68	5.58%	4.69%	-0.72%	-63.97%
4503	74 Outperform	$2.91T	35.46	5.46%	4.58%	14.29%	368.64%
4568	73 Outperform	$6.62T	22.50	18.32%	1.69%	14.09%	31.96%
4519	70 Outperform	$10.02T	25.35	21.48%	1.76%	10.29%	11.37%
4523	67 Neutral	$1.24T	24.69	5.96%	3.64%	9.43%	56.53%
Sector *	65 Neutral	¥339.25B	10.41	-0.16%	2.41%	10.21%	-11.90%

Astellas Pharma Corporate Events

Astellas Reports Strong Preliminary Sales for IZERVAY™ in Q1 FY2025

Astellas Pharma Inc. reported preliminary sales figures for its IZERVAY™ treatment for geographic atrophy secondary to age-related macular degeneration, totaling ¥15.9 billion or $110 million in the U.S. for the first quarter of FY2025. This announcement was made in conjunction with an investment community meeting, with further details to be discussed in the upcoming Q1 earnings call, highlighting the company’s ongoing efforts to strengthen its market position in ophthalmology.

The most recent analyst rating on (JP:4503) stock is a Hold with a Yen1750.00 price target. To see the full list of analyst forecasts on Astellas Pharma stock, see the JP:4503 Stock Forecast page.

Astellas Pharma Continues Performance-linked Stock Schemes for Executives

Astellas Pharma Inc. announced the continuation of its Performance-linked Stock Compensation and Stock Delivery Schemes for its executives, aimed at aligning management incentives with the company’s long-term value growth. These schemes, which include the BIP Trust for corporate executives and the ESOP Trust for group executives, are designed to enhance transparency and focus on increasing enterprise and shareholder value.

The most recent analyst rating on (JP:4503) stock is a Hold with a Yen1750.00 price target. To see the full list of analyst forecasts on Astellas Pharma stock, see the JP:4503 Stock Forecast page.

Astellas Pharma Continues Performance-linked Stock Compensation Scheme for 2025

Astellas Pharma has announced the continuation of its Performance-linked Stock Compensation Scheme for fiscal year 2025, aimed at incentivizing its directors. This scheme, which employs a Board Incentive Plan (BIP) Trust, aligns executive compensation with the company’s long-term growth and shareholder value, reflecting a strategic focus on enhancing enterprise value.

The most recent analyst rating on (JP:4503) stock is a Hold with a Yen1750.00 price target. To see the full list of analyst forecasts on Astellas Pharma stock, see the JP:4503 Stock Forecast page.

Astellas Pharma Announces Changes to Board of Directors

Astellas Pharma Inc. has announced a significant change in its Board of Directors, proposing the appointment of Andreas Busch and Mark Enyedy as new candidates at its upcoming Annual Shareholders Meeting. This move is intended to enhance the board’s diversity and effectiveness, reflecting stakeholder input and aiming to strengthen the company’s position in the global pharmaceutical industry.